TotalMarketCap

Lineage Cell Therapeutics

LCTXNYSE United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$247.293 M

$0.98 -5.07%

Close of 6 Nov 2026

As of 6 Nov 2026, Lineage Cell Therapeutics (LCTX) has a market capitalization of $247.3M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$14.6M

#3058 by revenue

Earnings

-$63.5M

Loss-making

Shares outstanding

252,907,464

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #88Century TherapeuticsIPSC$273.4M
  2. #89SAB BiotherapeuticsSABS$266.6M
  3. #90Lineage Cell TherapeuticsLCTX$247.3M
  4. #91Lexeo TherapeuticsLXEO$239.6M
  5. #92Fate TherapeuticsFATE$225.9M

What if Lineage Cell Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$111,649.03

Per share 114,184× higher

Bitcoin $1.53T

$6,041.13

Per share 6,178× higher

Apple $5.02T

$19,832.48

Per share 20,283× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for Lineage Cell Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.